Skylands Capital LLC Buys 26,195 Shares of Cytosorbents Co. (NASDAQ:CTSO)

Skylands Capital LLC boosted its stake in Cytosorbents Co. (NASDAQ:CTSO) by 1.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,781,622 shares of the medical research company’s stock after acquiring an additional 26,195 shares during the quarter. Skylands Capital LLC owned 0.05% of Cytosorbents worth $2,531,000 as of its most recent SEC filing.

Separately, Geode Capital Management LLC increased its stake in Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research note on Monday, January 13th. Finally, StockNews.com started coverage on shares of Cytosorbents in a research note on Saturday. They issued a “hold” rating on the stock. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Price Performance

Shares of CTSO opened at $1.15 on Monday. Cytosorbents Co. has a 52 week low of $0.70 and a 52 week high of $1.61. The firm has a market cap of $62.88 million, a P/E ratio of -3.19 and a beta of 0.61. The firm’s 50-day simple moving average is $1.01 and its 200 day simple moving average is $1.04. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.